EMA Recommends Granting a Marketing Authorisation for Tarlatamab By Ogkologos - April 17, 2026 56 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the treatment of adult patients with extensive-stage SCLC Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR New Super-Microsurgical Procedure May Prevent Lymphedema in Breast Cancer Patients March 2, 2020 Doctors Think Woman Has A Brain Tumor, But Then They Open... June 17, 2019 Gym Offers Free Membership & Support To Those Struggling With Addiction October 25, 2021 FDA Approves Tremelimumab in Combination with Durvalumab for Unresectable Hepatocellular Carcinoma October 27, 2022 Load more HOT NEWS Risk Tool Predicts Severe Chemotherapy Toxicity in Elderly Patients with Early... New on NCI Websites for July 2019 What to Know About Navigating Cancer Care With a Disability: An... Ability of Deep Learning to Accurately Diagnose Frequent STS Subtypes from...
